[go: up one dir, main page]

WO2014197816A8 - Nanocomplexes sensibles aux stimulus et leurs procédés d'utilisation - Google Patents

Nanocomplexes sensibles aux stimulus et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2014197816A8
WO2014197816A8 PCT/US2014/041332 US2014041332W WO2014197816A8 WO 2014197816 A8 WO2014197816 A8 WO 2014197816A8 US 2014041332 W US2014041332 W US 2014041332W WO 2014197816 A8 WO2014197816 A8 WO 2014197816A8
Authority
WO
WIPO (PCT)
Prior art keywords
nanocomplexes
methods
stimulus responsive
moiety
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/041332
Other languages
English (en)
Other versions
WO2014197816A1 (fr
Inventor
Kevin Yu-ming LIN
Sangeeta N. Bhatia
Gabriel Abner KWONG
Justin Han-je LO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of WO2014197816A1 publication Critical patent/WO2014197816A1/fr
Publication of WO2014197816A8 publication Critical patent/WO2014197816A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des nanocomplexes sensibles aux stimulus comprenant une fraction de masquage, par ex., une peptide, et une fraction thérapeutique, par ex., un anticoagulant. L'invention concerne également des méthodes de traitement ou de prévention d'un état, tel qu'un état hypercoagulable, par ex., des troubles de coagulation sanguine ou une maladie cardiovasculaire, chez un sujet.
PCT/US2014/041332 2013-06-06 2014-06-06 Nanocomplexes sensibles aux stimulus et leurs procédés d'utilisation Ceased WO2014197816A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831916P 2013-06-06 2013-06-06
US61/831,916 2013-06-06

Publications (2)

Publication Number Publication Date
WO2014197816A1 WO2014197816A1 (fr) 2014-12-11
WO2014197816A8 true WO2014197816A8 (fr) 2015-04-30

Family

ID=51033561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/041332 Ceased WO2014197816A1 (fr) 2013-06-06 2014-06-06 Nanocomplexes sensibles aux stimulus et leurs procédés d'utilisation

Country Status (2)

Country Link
US (1) US20140364368A1 (fr)
WO (1) WO2014197816A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754072C (fr) 2009-03-02 2019-01-15 Massachusetts Institute Of Technology Procedes et produits pour etablir un profil enzymatique in vivo
CA3214092A1 (fr) 2011-03-15 2012-09-20 Massachusetts Institute Of Technology Detection multiplexee avec rapporteurs contenant un isotope d'identification
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
US11448643B2 (en) 2016-04-08 2022-09-20 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
WO2017193070A1 (fr) * 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Méthodes et utilisations aux fins de mesures d'activité protéasique déclenchées à distance
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
WO2020068920A2 (fr) * 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Nanocapteurs de protéases pulmonaires et leurs utilisations
EP3911753A1 (fr) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Capteurs pour détecter et imager une métastase cancéreuse
WO2020191416A2 (fr) 2019-02-28 2020-09-24 Georgia Tech Research Corporation Compositions et procédés de profilage à porte logique d'activité biologique
CA3194956A1 (fr) 2020-09-11 2022-03-17 Glympse Bio, Inc. Detection d'activite de protease ex vivo pour la detection/le diagnostic, la stadification, le suivi et le traitement de maladies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023078A (en) * 1988-08-10 1991-06-11 Albert P. Halluin Plasminogen activator-heparin conjugates
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
SE470006B (sv) * 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
WO2000033888A2 (fr) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Composes de promedicaments et procede de preparation
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
WO2002060488A1 (fr) * 2001-01-30 2002-08-08 Universite Catholique De Louvain Composes antitumoraux
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7985401B2 (en) * 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) * 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
JP4897792B2 (ja) * 2005-04-20 2012-03-14 ビロメッド カンパニー， リミテッド 融合タンパク質の分離のための組成物および方法
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
KR101095841B1 (ko) * 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
AU2010215761B2 (en) * 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
US10167319B2 (en) * 2010-05-29 2019-01-01 Ben-Gurion University Of Negev Research & Development Authority Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
WO2013016578A2 (fr) * 2011-07-26 2013-01-31 University Of Southern California Libération contrôlée de produits biopharmaceutiques oculaires au moyen de polymères protéiques biosensibles
WO2013036743A1 (fr) * 2011-09-09 2013-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents d'imagerie pour imagerie d'activité protéase et leurs utilisations
WO2013049521A2 (fr) * 2011-09-29 2013-04-04 Virginia Commonwealth University Administration de médicament activée par la lumière
WO2014052462A2 (fr) * 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Anticorps activables qui se lient au récepteur d'interleukine-6 et procédés d'utilisation de ces derniers
WO2014089146A1 (fr) * 2012-12-04 2014-06-12 Isis Pharmaceuticals, Inc. Compositions et procédés pour une administration in vivo de composés anti-sens
DK2938360T3 (da) * 2012-12-28 2019-11-25 Cobiores Nv Minimalt toksiske prodrugs

Also Published As

Publication number Publication date
WO2014197816A1 (fr) 2014-12-11
US20140364368A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
WO2014197816A8 (fr) Nanocomplexes sensibles aux stimulus et leurs procédés d'utilisation
WO2014176128A3 (fr) Compositions et méthodes pour le traitement et le diagnostic de la grippe
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP3357921A3 (fr) Composes biaryles utiles dans le traitement de maladies humaines en oncologie, neurologie et immunologie
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
MX388142B (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
WO2015031808A3 (fr) Procédés de diagnostic et compositions pour le traitement d'un glioblastome
WO2017181079A3 (fr) Méthodes de surveillance et de traitement du cancer
WO2015191934A8 (fr) Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
WO2015066302A3 (fr) Compositions, méthodes d'utilisation et méthodes de traitement
WO2015015378A3 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
EP3495398A4 (fr) Copolymère ainsi que membrane de séparation, dispositif médical et purificateur de sang dans lesquels ledit copolymère est utilisé
WO2015106215A3 (fr) Compositions pharmaceutiques comprenant le 15-hepe et méthodes de traitement de l'asthme et de pathologies pulmonaires à l'aide desdites compositions
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2015038634A3 (fr) Dosage diagnostique multiplex pour la maladie de lyme et d'autres maladies transmises par les tiques
EP3060259A4 (fr) Procédés pour traiter ou prévenir des maladies vasculaires de la rétine
EP4342544A3 (fr) Amélioration de l'activité thérapeutique d'un inhibiteur de point de contrôle immunitaire
WO2016102930A3 (fr) Dispositif médical conçu pour traiter une veine
WO2016020882A3 (fr) Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
WO2015085314A3 (fr) Méthodes pour la détection d'une insuffisance cardiaque
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
EP4089109A3 (fr) Procédés de préparation du facteur willebrand modifié
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14734359

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14734359

Country of ref document: EP

Kind code of ref document: A1